Pharmaceutical giant Abbott Laboratories and UW-Madison spin-off Deltanoid Pharmaceuticals Inc. today announced the completion of an option and license agreement to develop a new generation of vitamin D receptor activators (VRDAs) for the treatment of kidney disease.
Office of Strategic Communication